Restricting IGF2BP1 expression resulted in increased sensitivity of leukemia cells to doxorubicin, cytarabine, and cyclophosphamide (Elcheva et al., 2020), showing promising potential for chemoresistance therapy. The gene discussed is IGF2BP1; the disease is leukemia.